Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/r in HER2-Negative Metastatic Breast Cancer
NCT03890744Phase 2Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ModraDoc006 in breast cancer, sponsored by Modra Pharmaceuticals. Started Jan 2019; status: completed.
02
Drugs
ModraDoc006
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03890744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890744.